Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study

Aihara M, Lu F, Kawata H, Iwata A, Odani-Kawabata N.

2021
Japanese journal of ophthalmology

View publication

Therapeutic Area

Glaucoma
Categories

Clinical development

Affiliations

Ophthalmology, University of Tokyo, Tokyo, Japan; Santen Inc., 6401 Hollis Street, Suite 125, Emeryville, CA, 94608, USA. Fenghe.Lu@santen.com; Santen Pharmaceutical Co., Ltd., Osaka, Japan; Santen Inc., 6401 Hollis Street, Suite 125, Emeryville, CA, 94608, USA

Related Publications

Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: 2-year Results from a Randomized, Multicenter Study

Panarelli JF, Moster MR, Garcia-Feijoo J, Flowers BE, Baker ND, Barnebey HS, Grover DS, Khatana AK, Lee B, Nguyen T, Stiles MC, Sadruddin O, Khaw PT.

Omidenepag Isopropyl in Latanoprost Low/Non-Responders with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3, Non-Randomized, Two-Phase, Open-Label Study

Panarelli JF, Bowden EC, Tepedino ME, Odani-Kawabata N, Pei Z, McLaurin EB, Ropo A.

The Development of a SIBS Shunt to Treat Glaucoma

Pinchuk L.

View all Glaucoma publications

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022